Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.82 |
| ▸ | HTR2C | P28335 | 11/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926587 | 0.91 | MCHR1 (0.84) | MCHR1HTR2C | |
| SCHEMBL2926180 | 0.91 | MCHR1 (0.82) | MCHR1HTR2C | |
| SCHEMBL2926451 | 0.91 | MCHR1 (0.82) | MCHR1HTR2C | |
| SCHEMBL2926448 | 0.90 | MCHR1 (0.81) | MCHR1HTR2C | |
| SCHEMBL2926947 | 0.90 | MCHR1 (0.82) | MCHR1HTR2C | |
| SCHEMBL5645431 | 0.90 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL2927588 | 0.90 | MCHR1 (0.80) | MCHR1HTR2C | |
| SCHEMBL2921113 | 0.90 | MCHR1 (0.80) | MCHR1HTR2C | |
| SCHEMBL6308019 | 0.89 | MCHR1 (0.67) | MCHR1HTR2CABL1KITABL2 | |
| SCHEMBL5647747 | 0.89 | MCHR1 (0.98) | MCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684766-B1 | PROCESS FOR THE PREPRATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-10-29 | — | — | EP | claimed |
| EP-3853237-B1 | PHOSPHONATE-CONTAINING CROSSLINKERS | UNIV UTRECHT HOLDING BV (NL) | 2024-04-24 | — | — | EP | claimed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1131273-B1 | 1,4-DIARYL-2-FLUORO-1-BUTEN-3-OL COMPOUNDS AND THEIR USE IN THE PREPARATION OF 1,4-DIARYL-2-FLUORO-1,3-BUTADIENE AND 1,4-DIARYL-2-FLUORO-2-BUTENE COMPOUNDS | BASF AG (DE) | 2003-10-22 | — | — | EP | claimed |
| EP-0982308-B1 | Derivatives of the 8H-(2,3-b)-pyrrolizine-8-one, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-02-26 | — | — | EP | claimed |
| EP-0983249-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED INDAZOLE DERIVATIVES | PFIZER PROD INC (US) | 2002-03-13 | — | — | EP | claimed |
| EP-0646116-B1 | PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER (US) | 1999-10-13 | — | — | EP | claimed |
| EP-0302788-B1 | 2-[Methyl(4-piperidinyl)]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b] indole derivatives, their preparation and therapeutical use | SYNTHELABO (FR) | 1992-02-05 | — | — | EP | claimed |
| EP-0099859-B1 | PROCESS FOR DYEING DIFFERENTIAL-DYEING FIBRES | CIBA-GEIGY AG (CH) | 1987-04-01 | — | — | EP | claimed |
| EP-0082523-B1 | INTERMEDIATES FOR THE PREPARATION OF 4-PHENYL-1,3-BENZODIAZEPINS AND METHODS FOR PREPARING THE INTERMEDIATES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-04-02 | — | — | EP | claimed |
| EP-0044808-B1 | N-PHENYLSULFONYL-N'-PYRIMIDINYL- AND -TRIAZINYL UREAS | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | claimed |
| EP-0044808-A2 | N-phenylsulfonyl-N'-pyrimidinyl- and -triazinyl ureas | CIBA-GEIGY AG (CH) | 1982-01-27 | — | — | EP | claimed |
| EP-2231644-B1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBVIE DEUTSCHLAND (DE) | 2014-01-15 | — | — | EP | disclosed |
| EP-2623504-A1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | Abbott GmbH & Co. KG (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-2231643-B1 | Amidomethyl-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBOTT GMBH & CO KG (DE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2231644-A2 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-0103537-A2 | N-arylsulfonyl-N'-triazolyl urea | CIBA-GEIGY AG (CH) | 1984-03-21 | — | — | EP | disclosed |
| EP-0099859-A1 | Process for dyeing differential-dyeing fibres | CIBA-GEIGY AG (CH) | 1984-02-01 | — | — | EP | disclosed |
| EP-0099339-A2 | Condensed N-phenylsulfonyl-N'-pyrimidinyl and triazinyl urea | CIBA-GEIGY AG (CH) | 1984-01-25 | — | — | EP | disclosed |
| EP-0034122-B1 | TRIPEPTIDE DERIVATIVES AND THEIR USE IN THE DETERMINATION OF ENZYMES | Pentapharm A.G. (CH) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | MCHR1 1/4885HTR2C 107/4885ABL1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.